301246 Stock Overview
Engages in the production and sale of pharmaceutical products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.57 |
| 52 Week High | CN¥26.30 |
| 52 Week Low | CN¥10.58 |
| Beta | 0 |
| 1 Month Change | -11.48% |
| 3 Month Change | 34.16% |
| 1 Year Change | -42.80% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -65.27% |
Recent News & Updates
Does Hubei Hongyuan Pharmaceutical Technology (SZSE:301246) Have A Healthy Balance Sheet?
Dec 18
Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%
Oct 08Recent updates
Does Hubei Hongyuan Pharmaceutical Technology (SZSE:301246) Have A Healthy Balance Sheet?
Dec 18Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%
Oct 08Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable
Aug 23Hubei Hongyuan Pharmaceutical Technology's (SZSE:301246) Soft Earnings Are Actually Better Than They Appear
Apr 29Getting In Cheap On Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) Is Unlikely
Mar 14Shareholder Returns
| 301246 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.8% | -1.9% | -1.2% |
| 1Y | -42.8% | -1.8% | 11.8% |
Return vs Industry: 301246 underperformed the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 301246 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 301246 volatility | |
|---|---|
| 301246 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 301246 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301246's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,075 | Shuangxi Xu | www.hbhypharm.com |
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, engages in the production and sale of pharmaceutical products in China and internationally. It provides active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, triamine, diacetyl guanine, guanine, and diacetylacyclovir; organic chemical raw materials comprising fluoride salts, glyoxal, and oxalic acid; and new energy materials consisting of lithium hexafluorophosphate. The company was founded in 2002 and is headquartered in Huanggang, China.
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Fundamentals Summary
| 301246 fundamental statistics | |
|---|---|
| Market cap | CN¥5.80b |
| Earnings (TTM) | CN¥27.01m |
| Revenue (TTM) | CN¥1.82b |
214.7x
P/E Ratio3.2x
P/S RatioIs 301246 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301246 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.82b |
| Cost of Revenue | CN¥1.64b |
| Gross Profit | CN¥178.98m |
| Other Expenses | CN¥151.97m |
| Earnings | CN¥27.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.068 |
| Gross Margin | 9.84% |
| Net Profit Margin | 1.49% |
| Debt/Equity Ratio | 8.3% |
How did 301246 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield74%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 07:56 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|